Latest Breaking News On - Longeveron or company - Page 3 : comparemela.com

UPDATE -- Longeveron Announces $2 36 Million Registered

MIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing.

United statesNew yorkMike moyerExchange commission onLongeveron or companyHc wainwright coExchange commissionLongeveron incAging related frailtySecurities actPrivate securities litigation reform actAnnual reportQuarterly reportsNasdaq lgvn

UPDATE -- Longeveron Announces $2 36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

UPDATE -- Longeveron Announces $2 36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkMike moyerHc wainwright coExchange commissionLongeveron or companyLongeveron incExchange commission onAging related frailtySecurities actPrivate securities litigation reform actAnnual reportQuarterly reports

Longeveron (LGVN) Reports Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial

Longeveron (LGVN) Reports Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Longeveron incLongeveron or companyAging related frailtyDiffusion tensor imagingMontreal cognitive assessmentMini mental state examinationDisease related qualityAlzheimer related imagine abnormalitiesMagnetic resonance imaging

Long-term Survival Data from Longeveron s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association – IT Business Net

Long-term Survival Data from Longeveron s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesSunjay kaushalMike moyerDrug administrationBlood instituteLongeveron incNational heartCompany quarterlyScientific sessions of the american heart associationLongeveron or companyNational institute of health heartExchange commissionExtended follow up data show continuedTransplant free survivalSupport continued investigationAging related frailty

Long-term Survival Data from Longeveron s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association

Long-term Survival Data from Longeveron s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesContactmike moyerlifesci advisorstelSunjay kaushalNational institute of health heartCompany quarterlyLongeveron incLongeveron or companyNational heartBlood instituteScientific sessions of the american heart associationDrug administrationExchange commissionExtended follow up data show continuedTransplant free survivalSupport continued investigationAging related frailty